| Recruiting | Ruxolitinib Maintenance Post-Hematopoietic Stem Cell Transplant T-Cell Lymphoma NCT07356245 | Jonathan Brammer | Phase 2 |
| Recruiting | A Phase I Trial Anti-CC Chemokine Receptor 4 Chimeric Antigen Receptor T Cells (CCR4 CAR T Cells) for CCR4 Exp NCT07055477 | National Cancer Institute (NCI) | Phase 1 |
| Recruiting | Ropeginterferon in Patients w/Cutaneous T-Cell Lymphoma (CTCL) NCT07047885 | H. Lee Moffitt Cancer Center and Research Institute | Phase 1 |
| Not Yet Recruiting | A Clinical Trial in Adults With Non-Hodgkin Lymphoma (NHL), With a Particular Emphasis on Cutaneous T Cell Lym NCT06385522 | Boston Immune Technologies and Therapeutics | Phase 1 |
| Recruiting | Combating Cancer-Related Fatigue: A Personalized Supportive Care Program NCT06860880 | UNC Lineberger Comprehensive Cancer Center | N/A |
| Recruiting | A Phase 2 Trial to Assess Safety and Efficacy of Tofacitinib 2% Cream in the Treatment of Cutaneous T-cell Lym NCT06698822 | M.D. Anderson Cancer Center | Phase 2 |
| Recruiting | Systemic Therapies in the Treatment of Cutaneous T-cell Lymphoma NCT06588868 | Fondazione Italiana Linfomi - ETS | — |
| Recruiting | Confirmatory Study of Topical HyBryte™ vs. Placebo for the Treatment of CTCL NCT06470451 | Soligenix | Phase 3 |
| Not Yet Recruiting | Characterization of the Microbiome in Cutaneous T Cell Lymphoma Skin Lesions Before and After Use of APR-TD011 NCT05728879 | Northwestern University | EARLY_Phase 1 |
| Recruiting | JAK1 Inhibitor Golidocitnib for the Treatment of Relapsed/Refractory Indolent T/NK-cell Lymphomas NCT06716658 | Institute of Hematology & Blood Diseases Hospital, China | Phase 2 |
| Not Yet Recruiting | Pilot Study to Characterize the Microbiome in Cutaneous T Cell Lymphoma Skin Lesions Before and After Use of C NCT06665490 | Northwestern University | — |
| Not Yet Recruiting | Evaluation of the KIR3DL2 Marker in Flow Cytometry for Sézary Syndrome Diagnosis, Therapeutic Response and Res NCT06651203 | Assistance Publique - Hôpitaux de Paris | — |
| Completed | Real World Experience With Mogamulizumab in the Treatment of Cutaneous T-cell Lymphoma NCT06113081 | Fondazione Italiana Linfomi - ETS | — |
| Recruiting | A Study of Molecular Subtyping-based Therapeutic Strategies for Cutaneous T-cell Lymphoma NCT06436677 | Peking University First Hospital | — |
| Recruiting | Novel Flow-cytometry Approaches to Improve the Detection of Tumor Cells in CTCL NCT06382844 | Instituto de Investigación Biomédica de Salamanca | — |
| Recruiting | Phase 1 Trial of ST-001 nanoFenretinide in Relapsed/Refractory T-cell Non-Hodgkin Lymphoma NCT04234048 | SciTech Development, Inc. | Phase 1 |
| Recruiting | Pembrolizumab and Mogamulizumab in Advanced-stage, Relapsed/Refractory Cutaneous T-cell Lymphomas NCT05956041 | University of Michigan Rogel Cancer Center | Phase 2 |
| Completed | Treatment of Mycosis Fungoides With Hypericin Ointment and Visible Light NCT05872854 | Ellen Kim, MD | Phase 2 |
| Unknown | Phase I/II Study of Linperlisib Plus Chidamide for R/R Cutaneous T-cell Lymphoma: a Prospective, Single-center NCT06037239 | Peking Union Medical College Hospital | Phase 1 / Phase 2 |
| Active Not Recruiting | A Study to Evaluate the Efficacy and Safety of KW-0761 in Chinese Subjects With Mycosis Fungoides or Sézary Sy NCT06285370 | Kyowa Kirin China Pharmaceutical Co., Ltd. | Phase 4 |
| Recruiting | Mogamulizumab and Brentuximab Vedotin in CTCL and Mycosis Fungoides NCT05414500 | University of Alabama at Birmingham | Phase 1 |
| Recruiting | MORPHEE : Mechanisms of Cell Death Induced by Extracorporeal Photochemotherapy NCT05333367 | Centre Hospitalier Universitaire de Besancon | N/A |
| Withdrawn | Triamcinolone Acetonide Injections in Primary Cutaneous Lymphoma Plaques With a Novel Needle-free Drug-deliver NCT05106192 | Case Comprehensive Cancer Center | N/A |
| Recruiting | A Study of Bexarotene Combined With Radiotherapy in People With Mycosis Fungoides NCT05296304 | Memorial Sloan Kettering Cancer Center | Phase 1 |
| Unknown | A Phase I Trial of SIM1811-03 in Subjects With Advanced Tumors NCT05781386 | Jiangsu Simcere Biologics Co., Ltd | Phase 1 |
| Not Yet Recruiting | TOtal Skin Electron Beam Therapy (Low-dose) for Tumor Clone Eradication in Early-stage Mycosis Fungoides NCT05205902 | Assistance Publique - Hôpitaux de Paris | Phase 3 |
| Completed | A Phase 1, Open-label Study of the Absorption, Metabolism, Excretion of [14C]-Resminostat NCT04955340 | 4SC AG | Phase 1 |
| Recruiting | Photopheresis in Early-stage Mycosis Fungoides NCT05680558 | Columbia University | Phase 2 |
| Completed | Romidepsin, CC-486 (5-azacitidine), Dexamethasone, and Lenalidomide (RAdR) for Relapsed/Refractory T-cell Mali NCT04447027 | National Cancer Institute (NCI) | Phase 1 |
| Recruiting | A Pilot of a Microdevice For In Situ Candidate Drug Screening in Cutaneous Lesions of T-Cell Lymphoma NCT04045470 | Dana-Farber Cancer Institute | N/A |
| Unknown | Sintilimab Plus Chidamide in the Treatment of Relapsed and Refractory Cutaneous T-cell Lymphoma: a Multicenter NCT04296786 | Peking Union Medical College Hospital | Phase 2 |
| Recruiting | Post-authorization Safety Study of Allogeneic Hematopoietic Stem Cell Transplantation in Patients Treated With NCT04014374 | Kyowa Kirin, Inc. | — |
| Unknown | Study Evaluating GZ17-6.02 in Patients With Advanced Solid Tumors or in Combination With Capecitabine in Metas NCT03775525 | Genzada Pharmaceuticals USA, Inc. | Phase 1 |
| Recruiting | Characterization of the Microbiome in Cutaneous T Cell Lymphoma NCT03932279 | Northwestern University | — |
| Active Not Recruiting | A Trial Assessing the Effect of Pembrolizumab Combined with Radiotherapy in Patients with Relapsed, Refractory NCT03385226 | University College, London | Phase 2 |
| Active Not Recruiting | Study of CAR-T Cells Expressing CD30 and CCR4 for r/r CD30+ HL and CTCL NCT03602157 | UNC Lineberger Comprehensive Cancer Center | Phase 1 |
| Completed | Study of BGB-A317 in Participants With Relapsed or Refractory Mature T- and NK-cell Neoplasms NCT03493451 | BeiGene | Phase 2 |
| Withdrawn | Radiation Therapy Plus Durvalumab for Tumor-Stage Cutaneous T-Cell Lymphoma NCT03235869 | University of Michigan Rogel Cancer Center | EARLY_Phase 1 |
| Terminated | Doxycycline for the Treatment of Cutaneous T-Cell Lymphoma NCT02341209 | Rochester General Hospital | Phase 2 |
| Completed | A Safety, Efficacy and Pharmacokinetics Study of CD11301 for the Treatment of Cutaneous T-Cell Lymphoma (CTCL) NCT03292406 | Galderma R&D | Phase 2 |
| Completed | Mechlorethamine Induced Contact Dermatitis Avoidance Study NCT03380026 | Rochester Skin Lymphoma Medical Group, PLLC | Phase 2 |
| Completed | Romidepsin Maintenance After Allogeneic Stem Cell Transplantation NCT02512497 | Ohio State University Comprehensive Cancer Center | Phase 1 |
| Unknown | Mechanisms of Action of Photo(Chemo)Therapy in Skin Diseases NCT03340155 | Medical University of Graz | N/A |
| Completed | A Study of Tremelimumab and IV Durvalumab Plus Poly-ICLC in Subjects With Biopsy-accessible Cancers NCT02643303 | Ludwig Institute for Cancer Research | Phase 1 / Phase 2 |
| Unknown | Low Dose Total Skin Electron Beam Treatment (TSEBT) Followed by Maintenance Valchlor for Patients With Mycosis NCT02881749 | Thomas Jefferson University | Phase 2 |
| Completed | Study of Tinostamustine, First-in-Class Alkylating HDACi Fusion Molecule, in Relapsed/Refractory Hematologic M NCT02576496 | Mundipharma Research Limited | Phase 1 |
| Completed | Study of E7777 in Patients With Relapsed or Refractory Peripheral T-cell Lymphoma and Cutaneous T-cell Lymphom NCT02676778 | Eisai Co., Ltd. | Phase 2 |
| Completed | Micro Needle Array-Doxorubicin (MNA-D) in Patients With Cutaneous T-cell Lymphoma (CTCL) NCT02192021 | Falo, Louis, MD | Phase 1 |
| Completed | FLASH [Fluorescent Light Activated Synthetic Hypericin] Clinical Study: Topical SGX301 (Synthetic Hypericin) f NCT02448381 | Soligenix | Phase 3 |
| Unknown | Early Diagnosis of Mycosis Fungoides NCT02539472 | Assistance Publique - Hôpitaux de Paris | N/A |
| Completed | Study of IPH4102 in Patients With Relapsed/Refractory Cutaneous T-cell Lymphomas (CTCL) NCT02593045 | Innate Pharma | Phase 1 |
| Completed | Study on Therapy With Dimethylfumarate (DMF) in Patients With Cutaneous T Cell Lymphoma (CTCL) NCT02546440 | Universitätsmedizin Mannheim | Phase 2 |
| Completed | Long-term Use of Romidepsin in Patients With CTCL NCT02296398 | Northwestern University | — |
| Terminated | Poly ICLC, Radiation, and Romidepsin for Advanced Cutaneous T Cell Lymphoma NCT02061449 | NYU Langone Health | Phase 1 |
| Unknown | Helical Irradiation of Total Skin (HITS) for Cutaneous Lymphoma NCT02039895 | Far Eastern Memorial Hospital | N/A |
| Withdrawn | Trial of Curcumin in Cutaneous T-cell Lymphoma Patients NCT00969085 | M.D. Anderson Cancer Center | Phase 2 |
| Completed | Study of KW-0761 Versus Vorinostat in Relapsed/Refractory CTCL NCT01728805 | Kyowa Kirin, Inc. | Phase 3 |
| Completed | A Phase 3 Trial of Brentuximab Vedotin(SGN-35) Versus Physician's Choice (Methotrexate or Bexarotene) in Parti NCT01578499 | Millennium Pharmaceuticals, Inc. | Phase 3 |
| Terminated | Everolimus in Treating Cutaneous T-cell Lymphoma NCT01637090 | Adam Lerner | Phase 2 |
| Terminated | STAT3 in T Cells: At The Crossroads of Inflammation and Cancer NCT01663571 | NYU Langone Health | — |
| Completed | Topical Resiquimod for the Treatment of Early Stage Cutaneous T Cell Lymphoma (CTCL) NCT01676831 | Abramson Cancer Center at Penn Medicine | Phase 1 / Phase 2 |
| Completed | Carbohydrate Metabolism Disorder Frequency in Hypertriglyceridemia Induced by Bexarotene of Cutaneous T Cell L NCT01569724 | Rennes University Hospital | Phase 4 |
| Completed | Outcomes of Cutaneous T-Cell Lymphoma and Graft-Versus-Host Disease With Extracorporeal Photopheresis Treatmen NCT01460914 | Dartmouth-Hitchcock Medical Center | — |
| Terminated | Analysis of Cutaneous and Hematologic Disorders by High-Throughput Nucleic Acid Sequencing NCT01556828 | Stanford University | — |
| Terminated | Low-dose (12 Gy) TSEBT+Vorinostat Versus Low-dose TSEBT Monotherapy in Mycosis Fungoides NCT01187446 | Stanford University | Phase 1 / Phase 2 |
| Completed | Extension Study in Subjects Who Relapsed After Complete Response on Study KW-0761-001 NCT01226472 | Kyowa Kirin Co., Ltd. | Phase 2 |
| Completed | RAD001 Combined With CHOP in Newly Diagnosed Peripheral T-cell Lymphomas NCT01198665 | Samsung Medical Center | Phase 1 / Phase 2 |
| Unknown | Open-label Pilot Study of Lenalidomide (Revlimid) as Adjuvant Treatment for Refractory Cutaneous T Cell Lympho NCT01132989 | Florida Academic Dermatology Centers | Phase 2 |
| Completed | Pralatrexate and Bexarotene in Patients With Relapsed or Refractory Cutaneous T-cell Lymphoma NCT01134341 | Acrotech Biopharma Inc. | Phase 1 |
| Completed | Ph II of Non-myeloablative Allogeneic Transplantation Using TLI & ATG In Patients w/ Cutaneous T Cell Lymphoma NCT00896493 | Stanford University | Phase 2 |
| Terminated | Recalcitrant Pruritus in Cutaneous T-Cell Lymphoma NCT00863395 | University of Minnesota | Phase 1 / Phase 2 |
| Unknown | Tazarotene 0.1% Cream For the Treatment of Cutaneous T-Cell Lymphoma: A Prospective Study NCT00779896 | McGill University | Phase 1 / Phase 2 |
| Completed | A Study for Participants With Relapsed Cutaneous T-Cell Lymphoma NCT00744991 | Eli Lilly and Company | Phase 2 |
| Terminated | Study of Oral LBH589 in Patients With Cutaneous T-cell Lymphoma and Adult T-cell Leukemia/Lymphoma NCT00699296 | Novartis Pharmaceuticals | Phase 2 |
| Completed | Study of Pralatrexate in Patients With Relapsed or Refractory Cutaneous T-cell Lymphoma NCT00554827 | Acrotech Biopharma Inc. | Phase 1 |
| Terminated | Study of Oral LBH589 in Adult Participants With Refractory/Resistant Cutaneous T-Cell Lymphoma (CTCL) NCT00490776 | Novartis Pharmaceuticals | Phase 2 |
| Terminated | Topical Romidepsin to Treat Early-Stage Cutaneous T-Cell Lymphoma NCT01445340 | National Cancer Institute (NCI) | Phase 1 |
| Completed | A Study of APO866 for the Treatment of Cutaneous T-cell Lymphoma NCT00431912 | Valerio Therapeutics | Phase 2 |
| Completed | Study of Oral LBH589 in Adult Patients With Refractory Cutaneous T-Cell Lymphoma NCT00425555 | Novartis Pharmaceuticals | Phase 2 |
| Completed | LBH589 in Adult Patients With Advanced Solid Tumors or Cutaneous T-cell Lymphoma NCT00412997 | Novartis | Phase 1 |
| Terminated | A Phase II Clinical Trial of PXD101 in Patients With Recurrent or Refractory Cutaneous and Peripheral T-Cell L NCT00274651 | Valerio Therapeutics | Phase 2 |
| Completed | Effect of Denileukin Diftitox on Immune System in CTCL Patients NCT00254332 | University of Pittsburgh | — |
| Completed | Combination Drug Study of Bexarotene and Rosiglitazone to Treat CTCL NCT00178841 | Vanderbilt University | Phase 2 |
| Completed | Oral SAHA (Suberoylanilide Hydroxamic Acid) in Advanced Cutaneous T-cell Lymphoma (0683-001) NCT00091559 | Merck Sharp & Dohme LLC | Phase 2 |
| Completed | A Single Agent Phase II Study of Romidepsin (Depsipeptide, FK228) in the Treatment of Cutaneous T-cell Lymphom NCT00106431 | Celgene | Phase 2 |
| Recruiting | Blood, Urine, and Tissue Collection for Cutaneous Lymphoma, Eczema, and Atopic Dermatitis Research NCT00177268 | University of Pittsburgh | — |
| Completed | Retrospective Analysis of a Drug-Metabolizing Genotype in Cancer Patients and Correlation With Pharmacokinetic NCT00341939 | National Cancer Institute (NCI) | — |
| Completed | Immunization Against Tumor Cells in Sezary Syndrome NCT00099593 | University of Pittsburgh | Phase 2 |
| Completed | Photopheresis as an Interventional Therapy for the Treatment of CTCL (Cutaneous T-Cell Lymphoma, Mycosis Fungo NCT00221039 | M.D. Anderson Cancer Center | Phase 4 |
| Completed | Clinical Trial of HuMax-CD4, a New Drug to Treat Advanced Stage T-Cell Lymphoma in the Skin. NCT00071084 | Genmab | Phase 2 |
| Completed | Clinical Trial of HuMax-CD4, a New Drug to Treat Early Stage T-Cell Lymphoma in the Skin. NCT00071071 | Genmab | Phase 2 |
| Completed | In Vitro Evaluation of Immune Responses in Cutaneous T-Cell Lymphoma (CTCL) NCT00177190 | University of Pittsburgh | — |
| Completed | Study of Oral Bexarotene in Combination With Photopheresis for Treatment of Cutaneous T-Cell Lymphoma NCT00306969 | Boston University | Phase 1 / Phase 2 |
| Completed | Depsipeptide to Treat Patients With Cutaneous T-Cell Lymphoma and Peripheral T-Cell Lymphoma NCT00007345 | National Cancer Institute (NCI) | Phase 2 |
| Completed | A Study Of Deoxycoformycin(DCF)/Pentostatin In Lymphoid Malignancies NCT00038025 | M.D. Anderson Cancer Center | Phase 2 |